ERBB2 and breast carcinoma: For instance, the semi-quantitative evaluation of the sign of the human epidermal growth factor receptor 2 (HER2), as identified by immunohistochemistry (IHC), indicates the necessity of anti-HER2 therapies for a breast cancer patient.